Juris J Meier1, Michael A Nauck. 1. Diabetes Division, Department of Medicine I, St Josef-Hospital, Ruhr-University of Bochum, Gudrunstrasse 56, 44791, Bochum, Germany, Juris.meier@rub.de.
Abstract
AIMS/HYPOTHESIS: Incretin-based therapies have been suggested to increase the risk of pancreatitis, but the results of the available studies are controversial. Because results from prospective trials are limited by low statistical power, and because retrospective studies are often subject to bias, a pooled analysis of phase III clinical trials and two endpoint trials was performed. METHODS: Event numbers for acute pancreatitis and patient-years of exposure (PYOs) were obtained from representatives of the pharmaceutical companies, or by literature research. Data were pooled for glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl-peptidase 4 (DPP-4) inhibitors in comparison with their respective controls and expressed as exposure-adjusted incidence rates. RESULTS: A total of 38 cases of pancreatitis were reported in clinical trials with GLP-1 receptor agonists, comprising 17,775 PYOs. With the comparator treatment, nine events occurred in 5,863 PYOs. The pooled event rates were 2.1 and 1.5 per 1,000 PYOs, respectively, resulting in an OR of 1.39 (95% CI 0.67, 2.88). With DPP-4 inhibitors, 57 events were reported in 45,132 PYOs compared with 46 events in 38,883 PYOs with the comparator treatment. Pooled event rates were 1.3 and 1.2 per 1,000 PYOs, respectively, resulting in an OR of 1.07 (CI 0.72, 1.58). CONCLUSIONS/ INTERPRETATION: This analysis suggests a trend towards a slightly elevated risk of pancreatitis with GLP-1 receptor agonists. With DPP-4 inhibitors, no consistent trend was found. However, the incidence numbers of cases of pancreatitis were still very small, and the statistical power was limited. Future endpoint trials may help to provide a better estimate of the true risk of pancreatitis with incretin-based therapies.
AIMS/HYPOTHESIS: Incretin-based therapies have been suggested to increase the risk of pancreatitis, but the results of the available studies are controversial. Because results from prospective trials are limited by low statistical power, and because retrospective studies are often subject to bias, a pooled analysis of phase III clinical trials and two endpoint trials was performed. METHODS: Event numbers for acute pancreatitis and patient-years of exposure (PYOs) were obtained from representatives of the pharmaceutical companies, or by literature research. Data were pooled for glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl-peptidase 4 (DPP-4) inhibitors in comparison with their respective controls and expressed as exposure-adjusted incidence rates. RESULTS: A total of 38 cases of pancreatitis were reported in clinical trials with GLP-1 receptor agonists, comprising 17,775 PYOs. With the comparator treatment, nine events occurred in 5,863 PYOs. The pooled event rates were 2.1 and 1.5 per 1,000 PYOs, respectively, resulting in an OR of 1.39 (95% CI 0.67, 2.88). With DPP-4 inhibitors, 57 events were reported in 45,132 PYOs compared with 46 events in 38,883 PYOs with the comparator treatment. Pooled event rates were 1.3 and 1.2 per 1,000 PYOs, respectively, resulting in an OR of 1.07 (CI 0.72, 1.58). CONCLUSIONS/ INTERPRETATION: This analysis suggests a trend towards a slightly elevated risk of pancreatitis with GLP-1 receptor agonists. With DPP-4 inhibitors, no consistent trend was found. However, the incidence numbers of cases of pancreatitis were still very small, and the statistical power was limited. Future endpoint trials may help to provide a better estimate of the true risk of pancreatitis with incretin-based therapies.
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Amy G Egan; Eberhard Blind; Kristina Dunder; Pieter A de Graeff; B Timothy Hummer; Todd Bourcier; Curtis Rosebraugh Journal: N Engl J Med Date: 2014-02-27 Impact factor: 91.245
Authors: Michael Elashoff; Aleksey V Matveyenko; Belinda Gier; Robert Elashoff; Peter C Butler Journal: Gastroenterology Date: 2011-02-18 Impact factor: 22.682
Authors: Charles Pyke; R Scott Heller; Rikke K Kirk; Cathrine Ørskov; Steffen Reedtz-Runge; Peter Kaastrup; Anders Hvelplund; Linda Bardram; Dan Calatayud; Lotte Bjerre Knudsen Journal: Endocrinology Date: 2014-01-27 Impact factor: 4.736
Authors: Sonal Singh; Hsien-Yen Chang; Thomas M Richards; Jonathan P Weiner; Jeanne M Clark; Jodi B Segal Journal: JAMA Intern Med Date: 2013-04-08 Impact factor: 21.873
Authors: Teresa Vanessa Fiorentino; Michael Owston; Gregory Abrahamian; Stefano La Rosa; Alessandro Marando; Carla Perego; Eliana S Di Cairano; Giovanna Finzi; Carlo Capella; Fausto Sessa; Francesca Casiraghi; Ana Paez; Ashwin Adivi; Alberto Davalli; Paolo Fiorina; Rodolfo Guardado Mendoza; Anthony G Comuzzie; Mark Sharp; Ralph A DeFronzo; Glenn Halff; Edward J Dick; Franco Folli Journal: Am J Pathol Date: 2014-11-06 Impact factor: 4.307